Dominick Angiolillo, MD, PhD, on the TWILIGHT Trial Analysis of High-Risk Patients With Diabetes

In this podcast, Dominick J. Angiolillo, MD, PhD, provides insight into a new analysis of the TWILIGHT trial that he and his colleagues performed among high-risk patients with diabetes. It was a topic he discussed during ACC.20/WCC Virtual, when he presented the session, “Ticagrelor With and Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: Insights From the TWILIGHT Trial.”

 

Additional Resources:

  • Angiolillo DJ, Baber U, Sartori S, et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention [published online March 30, 2020]. J Am Coll Cardiol. doi:10.1016/j.jacc.2020.03.008
  • Angiolillo DJ. Ticagrelor with and without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention: insights from the TWILIGHT trial. Paper presented at: the American College of Cardiology Virtual Annual Scientific Session Together With World Congress of Cardiology; March 28-30, 2020; virtual. https://acc.mediasite.com/mediasite/play/b6c8a7c6fdd64b6597c8e19255c5c9ce1d?autoStart=true. Accessed April 20, 2020.
  • Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032-2042. doi:10.1056/NEJMoa1908419

 

Dominick J. Angiolillo, MD, PhD, is a professor in the Department of Medicine, Division of Cardiology, at the University of Florida College of Medicine — Jacksonville. There, he also serves as the medical director of the Cardiovascular Research Program, the program director of the Interventional Cardiology Fellowship Program, and the associate program director of the Cardiovascular Disease Fellowship.

Submit Feedback

Name